Detailed Mechanism Funding and Narrative

Years of mechanism: 2007 2008 2009

Details for Mechanism ID: 5292
Country/Region: Nigeria
Year: 2009
Main Partner: American Society for Microbiology
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: HHS/CDC
Total Funding: $350,000

Funding for Laboratory Infrastructure (HLAB): $350,000

ACTIVITY UNCHANGED FROM FY2008

This is a continuing activity with funding initiated in late COP07. ASM has the capacity to support the

PEPFAR program by ensuring that laboratories possess the necessary organizational and technical

infrastructure to provide quality laboratory testing and results in support of HIV prevention, care, and

treatment programs, especially for tuberculosis (TB) and opportunistic infections (OI). ASM can provide

technical assistance through carefully chosen experts from among ASM's more than 5,000 clinical

laboratory microbiologists and immunologists worldwide.

ASM will continue to focus on improving the quality and capacity of TB and OI diagnosis in Nigeria. The

following five activities will support this goal: 1) development of a comprehensive quality assurance (QA)

and quality control (QC) system for TB microscopy and culture, reviewing the existing guidelines on QA for

AFB microscopy and developing such for TB culture/DST, 2) review and make improvements to the TB

training curriculum (and SOP's) currently used in Nigeria, 3) provision of technical expertise on the

structural design of new and existing laboratories involved in diagnosis of TB (specifically, culture and drug

resistance testing), 4) improvement of training for simple OI diagnosis (microscopy) and 5) support offsite

training on TB culture and drug sensitivity for select PEPFAR-Nigeria laboratorians. ASM will work closely

with PEPFAR-Nigeria Lab Technical Working Group (LTWG) to ensure that these activities are coordinated

with the (Government of Nigeria) GON and those organizations currently supporting TB diagnosis and

treatment in Nigeria (including, UMD-ACTION, Harvard-APIN, German Leprosy Group, GHAIN, Netherlands

Leprosy Group, Damien Foundation of Belgium (DFB) and WHO. ASM will work through the LTWG to

ensure that activities and deliverables are developed and implemented in a harmonized fashion.

EMPHASIS AREAS: The major emphasis of this activity is local organizational and human capacity

development in quality assurance and quality improvement of laboratory testing.

POPULATIONS BEING TARGETED: ASM will develop/improve training programs provided to

laboratorians working in clinical health care facilities for improved diagnosis of TB and OIs. ASM will also

improve the infrastructure of laboratories where these individuals currently work.

REACHING THE VISION: This activity will enable ASM to reach its vision and long-term strategy of

building resource-poor countries' ability to better diagnose infectious diseases through quality-assured

laboratory procedures. The main emphasis is in transferring knowledge to Nigerian laboratorians thus

human capacity development via training and mentoring in order to ensure that the activity is sustained over

the years. ASM's activities also contribute to narrowing the gender gap in Nigeria by offering knowledge

transfer opportunities to both female and male Nigerian laboratorians.

LINKS TO OTHER USG RESOURCES/DONOR SUPPORT: While there is no direct link to other USG

resources and donor support, ASM places great emphasis on gathering information on what other donors

are doing, in order to prevent duplicating efforts and act more in a leveraging capacity.

New/Continuing Activity: Continuing Activity

Continuing Activity: 13102

Continued Associated Activity Information

Activity Activity ID USG Agency Prime Partner Mechanism Mechanism ID Mechanism Planned Funds

System ID System ID

13102 9847.08 HHS/Centers for The American 6391 5292.08 HHS/CDC Track $250,000

Disease Control & Society for 2.0 ASM

Prevention Microbiology

9847 9847.07 HHS/Centers for The American 5292 5292.07 Cooperative $500,000

Disease Control & Society for Agreement

Prevention Microbiology

Table 3.3.16: